Diagnosis and Drug Therapy of Prolactinoma
Authors:
- 1 June 1996
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 51 (6) , 954-965
Abstract
A prolactin-secreting pituitary tumour is the most frequent cause of hyperprolactinaemia that commonly occurs in clinical practice. Prolactinomas occur more frequently in women than in men and may...Keywords
This publication has 56 references indexed in Scilit:
- A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic AmenorrheaNew England Journal of Medicine, 1994
- Double blind randomized study using oral or injectable bromocriptine in patients with hyperprolactinaemiaClinical Endocrinology, 1994
- Cabergoline in the long-term therapy of hyperprolactinemic disordersEuropean Journal of Endocrinology, 1992
- Dopamine Agonists and Pituitary Tumor ShrinkageEndocrine Reviews, 1992
- CV 205–502 Treatment of Hyperprolactinemia*The Journal of Clinical Endocrinology & Metabolism, 1989
- Inhibition of Basal and Metoclopramide-Induced Prolactin Release by Cabergoline, an Extremely Long-Acting Dopaminergic DrugThe Journal of Clinical Endocrinology & Metabolism, 1987
- Bromocriptine-induced removal of endoplasmic membranes from prolactinoma cellsCellular and Molecular Life Sciences, 1985
- Prophylactic bromocriptine treatment during pregnancy in women with macroprolactinomas: report of 13 pregnanciesBJOG: An International Journal of Obstetrics & Gynaecology, 1984
- Pergolide for the Treatment of Pituitary Tumors Secreting Prolactin or Growth HormoneNew England Journal of Medicine, 1983
- Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomasCellular and Molecular Life Sciences, 1983